Abstract:Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a relatively uncommon, high-grade neuroendocrine tumor sharing several features with small-cell lung carcinoma (SCLC). LCNEC is considered aggressive, and the optimal treatment strategy and chemotherapy regimen remain undefined. We retrospectively evaluated a LCNEC patient cohort established from 1997 to 2015 at Mayo Clinic (Minnesota). A diagnosis of LCNEC was made when all WHO classification criteria were present in the tumor section examined. Clinical characteristics, treatment and outcomes were analyzed. Available radiology assessment was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. The study included 55 LCNEC patients. Median age at diagnosis was 63 years (range: 38-88); two thirds were men; and majority were smokers (94%). Clinical staging was I, II, III or IV in 52.8%, 9.1%, 14.5%, and 23.6% of cases, respectively. Forty-six percent of stage IV patients presented with brain metastases at time of diagnosis (n=6/13) and 18% (n=7/38) developed brain recurrence in the follow up period. Thirty-nine (71%) patients had surgery and 9 (16%) patients received adjuvant platinum-based chemotherapy. Sixty-five percent of patients with complete resection experienced disease recurrence with 80% recurring within 2 years of resection. Treatment data for first-line palliative chemotherapy were available on 23 patients: 10 received platinum/etoposide and 13 received other regimens. In 19 patients with available imaging; the overall response rate was 52.6% (95% CI, 31.7-72.7) and there was no difference in ORR between platinum/etoposide (ORR=55.6%) or platinum plus other agents (paclitaxel or pemetrexed; ORR=55.6%). The median survival time was 26.3 months (95%CI; 18.6-33.9); the 1-, 2-, 3- and 5-year overall survival rates (OS) were 75%, 53%, 36%, and 30%, respectively. Patients who received platinum/etoposide demonstrated longer median time to progression (TTP), and median OS than those who received ‘other’ regimens (14.7 months vs. 7.1 months; p value 0.07, and 28.2 months vs. 21.1 months; p value 0.22, respectively); the differences did not reach conventional statistical significance, likely due to the small sample size. Rigorous pathologic confirmation and genomic analysis are ongoing. LCNEC is associated with a poor prognosis and high recurrence rates after surgery. Advanced LCNEC patients are at high risk for brain metastases, therefore, routine brain imaging surveillance during follow-up may be beneficial. The chemotherapeutic responsiveness of LCNEC patients was intermediate between that of NSCLC and SCLC patients. Future prospective, multicenter, clinical trials are needed to determine the best chemotherapy regimen for these rare tumors.

Immunotherapy combined with chemotherapy for patients with pulmonary large cell neuroendocrine carcinoma

[Advances of Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma]

Efficacy of immune checkpoint inhibitors in advanced large cell neuroendocrine carcinoma of the lung: A single‐institution experience

Efficacy and safety of PD-1/PD-L1 inhibitor plus platinum-based chemotherapy vs. platinum-based chemotherapy alone in patients with previously untreated advanced large-cell neuroendocrine cancer of the lung.

Large Cell Neuroendocrine Carcinoma Of The Lungs: Case Report And Literature Review

Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma

Neoadjuvant immunotherapy in patients with pulmonary lymphoepithelioma-like carcinoma

Neoadjuvant immunochemotherapy for pulmonary large-cell neuroendocrine carcinoma: case report

Safety and Effectiveness of Neoadjuvant Immunotherapy Combined with Chemotherapy Followed by Surgical Resection in Patients with Stage I-IIIA Small-Cell Lung Cancer: a Retrospective Single-Arm Clinical Trial.

Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study

Perioperative serplulimab‐based chemoimmunotherapy in stage IV large cell neuroendocrine carcinoma of the lung: A case report

Exploration of Immunotherapy in Advanced Pulmonary Lymphoepithelioma‐Like Carcinoma

The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma

Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small Cell Lung Cancer: a Case Report

Durable Response to Combination Radiotherapy and Immunotherapy in EP-resistant Lung Large-Cell Neuroendocrine Carcinoma with B2M and STK11 Mutations: a Case Report.

P1.07-036 Large Cell Neuroendocrine Carcinoma of the Lung: the Mayo Clinic Experience

Disparity in Clinical Outcomes Between Pure and Combined Pulmonary Large-Cell Neuroendocrine Carcinoma: A Multi-Center Retrospective Study.

The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung

Complete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report

Clinical Challenges in Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer.

Efficacy of cadonilimab and anlotinib combination in treating multiple drug‐resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review